Offers a noninvasive, data-driven gait biomarker and analytic pipeline that could help monitor and stratify patient treatment responses in PD, but provides little mechanistic or therapeutic target information for drug discovery.

By enabling gold-standard correlation of longitudinal clinical, imaging, genetic, and biofluid biomarkers with neuropathology, this resource strengthens biomarker validation and translational readiness, indirectly supporting Parkinson's therapeutic discovery and trial development.

Although not a mechanistic or therapeutic study, this objective, low-cost biomarker method could improve monitoring, remote assessment, dose titration, and trial outcome measurement for dyskinesia, thereby aiding translational and clinical decision-making.

The device offers an accessible, real‑time tremor monitoring and diagnostic tool that can aid patient stratification and remote data collection for clinical studies, but it provides minimal insight into PD pathophysiology or direct therapeutic targets.

Although it lacks molecular or intervention insights, the study offers potentially useful cross-disease neuroimaging biomarkers for early detection and cohort stratification that could improve Parkinson's trial design and biomarker-driven therapeutic development.

This work offers a scalable, accessible diagnostic/screening tool that could aid early detection, monitoring, and patient stratification for clinical studies, but it provides little direct insight into mechanisms or therapeutic targets for Parkinson's disease.

The work has limited direct therapeutic discovery value—no mechanistic targets or interventions—but the multimodal diagnostic method could help early detection and patient stratification for Parkinson's clinical studies if rigorously validated on diverse cohorts.

The findings highlight geographic disparities in diagnosis, treatment access, and comorbidity management relevant for public-health planning and trial site selection, but provide limited actionable insight for molecular targets or therapeutic development.

Direct therapeutic-discovery value is low, but the findings matter for clinical translation and research conduct because clinicians and trialists must address and validate patient-sourced AI outputs to preserve shared decision-making, data quality, and safety.

Improves diagnostic accuracy and early detection workflows, but provides no mechanistic, biomarker, or therapeutic insights relevant to drug discovery, limiting its translational value for PD therapeutics.

The results are useful for healthcare planning and for designing clinical studies or care models by highlighting acute-care burden and persistent supportive-care needs, but the paper provides little mechanistic or therapeutic-discovery insight for Parkinson’s drug development.

It is relevant to Parkinson's research because it links immune-mediated BBB dysfunction and HLA-associated susceptibility to mechanisms that could yield immune-targeted therapies or biomarkers, though its broad, review-style treatment offers limited PD-specific actionable targets.

Provides proof-of-concept that non‑invasive, anatomically individualized temporal interference neuromodulation can acutely improve Parkinsonian motor symptoms and could be developed as a less invasive alternative to STN‑DBS, meriting larger trials to test durability, dosing, and specificity.

The multi-omics, colocalized genetic evidence prioritizes AMIGO1 as a genetically supported candidate for mechanistic follow-up and potential biomarker or therapeutic development in PD, though functional validation is still required.

Although not directly therapeutic, the model links DA/NA and STN population dynamics to decision-making deficits in Parkinson's disease, offering a mechanistic computational platform to generate testable hypotheses for neuromodulation strategies or noradrenergic-focused interventions.

By pinpointing the Golgi and postsynaptic sites and revealing astrocyte buffering of manganese, the work identifies cell-type and subcellular targets relevant to manganese-induced parkinsonism and suggests avenues for targeted neuroprotective strategies against environmental metal neurotoxicity.

The finding that cognitive domains in PD are temporally dynamic highlights the need to rethink diagnostic criteria, endpoint selection, and patient stratification in trials—potentially improving biomarker and clinical outcome design—though it offers little direct mechanistic or therapeutic targets.

Improved uptake of genetic testing enhances patient identification for genotype-stratified trials and precision-medicine approaches, but the study offers limited direct mechanistic or therapeutic insights.

While not revealing molecular targets, this identifies modifiable affective contributors and measurement considerations that could inform symptomatic treatments, patient selection, and outcome measures in PD trials.

This low-cost, portable platform enables point-of-care monitoring of GSH as an oxidative-stress biomarker relevant to Parkinson’s disease patient monitoring and stratification, but it offers limited direct mechanistic or therapeutic-discovery insights.

The work highlights oligodendrocyte/MOBP dysregulation as a shared neurodegeneration signal and a possible biomarker/target, but provides limited direct, PD-specific mechanistic or therapeutic leads for Parkinson's drug discovery.

If confirmed in larger cohorts, hearing impairment could serve as an early, potentially modifiable risk marker for Parkinson's disease dementia, informing screening and prevention strategies, but current findings are exploratory and underpowered.

Offers a language-specific, speaker-robust speech biomarker and feature-selection pipeline useful for remote staging and monitoring in PD clinical assessments and trials, but it provides little mechanistic or therapeutic discovery insight.

Direct therapeutic relevance to Parkinson's is limited, but the demonstrated ability to synthesize missing MRI contrasts (validated on PPMI data) can help recover incomplete imaging datasets and enable quantitative biomarker or longitudinal imaging studies in PD research.

Direct therapeutic relevance to Parkinson's is limited, but the approach—inferring cell-autonomous genetic/pathologic states from transcriptomic signatures—could be adapted to identify PD-relevant cellular states or biomarkers at single-cell resolution.